NL
EN
terug naar home
07-01-2020 Polyganics Achieves CE Mark Certification for LIQOSEAL® 25-02-2019 Pharming meldt presentatie van studie met RUCONEST® tijdens de jaarlijkse bijeenkomst van de American Academy of Allergy, Astma & Immunology (AAAAI) 31-10-2017 BioGeneration Ventures Fund III reaches EUR 82 million in final close 23-10-2017 Pharming meldt voor het merendeel niet-contante uitoefening van warrants en conversie van converteerbare obligaties in aandelen 18-10-2017 BioGeneration Venture’s portfolio onderneming SurgVision gekocht door Bracco Imaging 03-10-2017 Dutch Mellon Medical secures € 6 million for market introduction of major innovation in surgical suture technology: single-handed suturing using the Switch® 02-10-2017 Pharming meldt positieve klinische studiedata met RUCONEST® bij kinderen 26-09-2017 Pharming en de internationale patiëntenkoepel HAEi maken partnership bekend met Inceptua Medicines Access voor wereldwijde toegang van HAE-patiënten tot RUCONEST® 26-07-2017 Pharming maakt publicatie profylactische data RUCONEST® in medisch tijdschrift The Lancet bekend 21-07-2017 Pharming rondt herfinanciering met lening van US$100 miljoen af tegen verbeterde voorwaarden 12-07-2017 MammaPrint® van Agendia aanbevolen in specifieke update van Amerikaanse ASCO borstkankerrichtlijn op basis van gegevens uit de belangrijke MINDACT-studie 06-07-2017 Agendia’s MammaPrint® aanbevolen in belangrijke 2017 update van Internationale St. Gallen Borstkanker Richtlijn 03-04-2017 EUR 12,8 miljoen nieuwe financiering voor biotechonderneming Cristal Therapeutics 14-03-2017 BioGeneration Ventures contributes to Cristal Therapeutics EUR 12.8 million Financing Round 13-02-2017 Europese Commissie breidt marketingvergunning RUCONEST® uit met zelfstandige toediening 08-12-2016 Pharming rondt transactie met Valeant over terugkoop van alle Noord-Amerikaanse rechten RUCONEST® af 07-12-2016 Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal’s CriPec® nanotech platform 07-12-2016 Polyganics announces Birmingham Hand Centre efficacy study of nerve conduit NEUROLAC® in finger surgery

BioGeneration Ventures Fund III reaches EUR 82 million in final close

Bekijk hier de online versie

 
 
PRESS RELEASE
 
 
 
 
 
 

BioGeneration Ventures Fund III reaches EUR 82 million in final close

Investments from Bristol-Myers Squibb and Johnson & Johnson Innovation - JJDC

  • BioGeneration Ventures (BGV) closes its third fund, BGV III, at EUR 82 million exceeding its target to accommodate strong interest from private, institutional and strategic investors
  • Bristol-Myers Squibb and JJDC back European early stage innovation by investing in BGV III
  • Previously announced investors include the European Investment Fund (EIF)
  • Investment focus on entrepreneurship and innovation in therapeutics, medical devices and diagnostics in Europe

Naarden, The Netherlands, 31 October 2017 – BioGeneration Ventures (BGV) announces the final closing of its third fund, BGV III at EUR 82 million. Due to strong market interest, the fund has exceeded its original target of EUR 50 million. New investors include biopharmaceutical company Bristol-Myers Squibb, healthcare company Johnson & Johnson Innovation - JJDC, Inc. (JJDC) as well as private equity investor Schroder Adveq, and the MAN Pension Trust. BGV III is now one of the largest funds focused on seed investments in European biotechnology companies.

The new fund will build on the track record of the first two BGV funds which have yielded major successes. These include Dezima Pharma sold to Amgen for USD 1.5 billion and Acerta Pharma which at USD 7 billion was the largest private exit in Europe in the biotech sector to date. BGV was founding investor in both companies, which are typical examples of the biotech sector’s ability to generate so-called “unicorns” delivering outsized returns for investors.

The firm’s third fund will focus on therapeutics, medical devices and diagnostics, within Europe, in particular in the Benelux and Germany. Five investments have already been made from the fund into German immuno-oncology company Catalym, and Dutch companies Escalier Biosciences, Scenic Biotech, Varmx, and Mellon Medical working on autoimmune diseases, target discovery, haematology, and vascular suturing respectively.

Edward van Wezel, BGV’s Managing Partner said: “Over the last years, BGV has proven that investing in early stage companies is critical in developing innovative science to meet patients’ needs; it can be financially very attractive as well. We believe that support and close collaboration from Bristol-Myers Squibb and JJDC illustrate the increasing interest in early stage innovation. This also demonstrates the unique position that BGV has reached in this arena.”

Paul Biondi, Senior Vice President, Head of Business Development Bristol-Myers Squibbcommented: “Bristol-Myers Squibb recognises the potential of early stage innovations emerging from leading scientific groups in the European biotech scene.  We are committed to working with VC investors such as BGV who can identify the investment opportunities with the most potential to deliver transformational medicines.”

BGV operates as a joint venture with Forbion Capital Partners, providing access to the later stage perspective on early innovation and a global network of experts and pharma companies. The BGV team has broad experience in investment, life sciences, business development, and commercial operations. The team includes experienced biotech entrepreneurs as venture partners and advisors.

-Ends-

For further information:

BioGeneration Ventures
Edward van Wezel
E-mail: info@biogeneration.vc 
Tel:  +31 35 69 930 00 

LifeSpring Life Sciences Communication (for Dutch media)
Leon Melens
E-mail: lmelens@lifespring.nl
Tel: +31 6 538 16 427

Instinctif Partners (For other European media)
Dr Christelle Kerouedan / Melanie Toyne-Sewell
E-mail: BGV@instinctif.com
Tel: +44 20 7457 2020

Notes to Editors

About BioGeneration Ventures (BGV)

BioGeneration Ventures (BGV) is a venture capital company, with a focus on early stage European biotech, medtech, and diagnostics companies. BGV has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class teams. The Company manages over €100 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together.

BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realisation for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit.

Historical successful investments include divestment of Dezima Pharma to Amgen for up to USD 1.55 billion in total deal value and in Acerta Pharma for up to USD 7 billion with a guaranteed payment of USD 4 billion. Both companies were co-founded by BGV in 2012 and 2013 respectively. The Acerta Pharma sale was the largest exit ever of a privately held European biotech company.

BGV is based in Naarden, The Netherlands, and closely collaborates with Forbion Capital Partners.

www.biogenerationventures.com

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedInTwitterYouTube and Facebook.

About Johnson & Johnson Innovation - JJDC (JJDC)

Johnson & Johnson Innovation - JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson and a long-term investment partner to global healthcare entrepreneurs. Founded in 1973, JJDC continues a legacy of customizing deals for data-driven companies across the continuum of healthcare, with the goal of turning great ideas into transformative new pharmaceutical, medical device and consumer healthcare products.

 


 
 
 
 


 

 
 

Copyright © 2017 LifeSpring LifeSciences Communication, All rights reserved. 

 

Our address is: 
LifeSpring LifeSciences Communication
Science Park 400
1098 XH Amsterdam
Netherlands

 

www.lifespring.nl


 
 
Klik hier om u uit te schrijven

Science Park 400 Matrix II Building 1098 XH Amsterdam +31 (0)653816427
lmelens@lifespring.nl

  • - Corporate Communications
  • - Healthcare PR
  • - Financial Communications
  • - Content Marketing
  • - Social Media and Online Communications